Latest Breaking News On - Elias jabbour - Page 7 : comparemela.com

Iclusig Boosts MRD-Negative Complete Response in Ph-Positive ALL

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

United statesElias jabbourSchool of hematologic oncology annual meetingUniversity of texas md anderson cancer centerDivision of cancer medicineDepartment of leukemiaAdding iclusigHematologic oncology annualCancer medicineCancer centerAcute lymphoblastic leukemia

Ponatinib Plus Chemotherapy Elicits MRD-Negative Remissions in Certain Patients With ALL

Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.

United statesElias jabbourCancer networkUniversity of texas md anderson cancer centerSociety of hematologic oncologyDivision of cancer medicineDepartment of leukemiaHematologic oncologyCancer medicineCancer center

Ponatinib regimen improves outcomes in Ph+ acute lymphoblastic leukemia

Ponatinib regimen improves outcomes in Ph+ acute lymphoblastic leukemia
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesBymark leiserMindy valcarcelElias jabbourUniversity of texas md anderson cancer centerBristol myers squibbSociety of hematologic oncology annual meetingHematologic oncology annual meetingAdaptive biotechnologiesHematologic oncology annualCancer center

Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

United statesElias jabbourUniversity of texas md anderson cancer centerDivision of cancer medicineDepartment of leukemiaCancer medicineCancer centerSociety of hematologic oncology annual meeting sohoHematologic oncologyMinimal residual disease mrd negativePhase 3 phallcon trial nct03589326

Ponatinib Plus Low-Dose Chemotherapy Improves MRD– CR Rates in Newly Diagnosed Ph+ ALL

Elias Jabbour, MD, outlines additional findings from PhALLCON and their clinical implications for patients with Philadelphia chromosome-positive ALL

United statesElias jabbourDepartment of leukemiaUniversity of texas md anderson cancer centerCancer centerPatients with leukemiaAcute lymphocytic leukemiaThe university of texas md anderson cancer centerCleveland clinic lerner college of medicine case western reserve university